Cargando…
Interferon signature in systemic autoimmune diseases: what does it mean?
Autores principales: | Nocturne, Gaetane, Mariette, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723951/ https://www.ncbi.nlm.nih.gov/pubmed/36597991 http://dx.doi.org/10.1136/rmdopen-2022-002687 |
Ejemplares similares
-
Association between T follicular helper cells and T peripheral helper cells with B-cell biomarkers and disease activity in primary Sjögren syndrome
por: Dupré, Anastasia, et al.
Publicado: (2021) -
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2022) -
Machine Learning for the Identification of a Common Signature for Anti–SSA/Ro 60 Antibody Expression Across Autoimmune Diseases
por: Foulquier, Nathan, et al.
Publicado: (2022) -
Systemic Autoimmune Disease Among Adults Exposed to the September 11, 2001 Terrorist Attack
por: Miller‐Archie, Sara A., et al.
Publicado: (2020) -
CAR T cells for treating autoimmune diseases
por: Blache, Ulrich, et al.
Publicado: (2023)